Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and Therapeutics

Jae Hyeon Yu1,† , Sangwon Lee 2,3,† , Yoon Jung Kim 1, Won Young Kim 1, Min Jung Lee 1 and Yun Kim 1, *2024-09-032024-09-032024-09-03http://98.70.32.231:4000/handle/123456789/1339Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and TherapeuticsArticle